Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow eligible Medicare Part D patients to access certain obesity-indicated GLP-1 medications, including Foundayo, Wegovy, and certain Zepbound formulations, for no more than $50 per month through December 31, 2027
These services typically include: an online medical assessment prescription approval by a clinician medication delivery to the patients home Well-known UK providers may include: regulated online pharmacies private GP clinics specialist weight-management services When choosing a provider, it is important to confirm that the pharmacy is registered with the General Pharmaceutical Council (GPhC)
Naito Y, Fujii A, Sawada H, Oboshi M, Iwasaku T, Okuhara Y, Morisawa D, Eguchi A, Hirotani S, Masuyama T
Peptides should be stored in clean, chemically inert containers
& Chang, T
Whey protein supplementation and muscle mass: current perspectives